Correlation of clinicopathological parameters with EGFR and Her-2 neu status in oral cancer patients in a tertiary care centre

Authors

  • Varsha Dalal National Institute of Pathology, Indian Council of Medical Research
  • Kiran Alam J.N Medical College, AMU
  • Veena Maheshwari J.N Medical College, AMU
  • S.C Sharma J.N Medical College, AMU
  • Anshu Jain J.N Medical College, AMU
  • Roobina Khan J.N Medical College, AMU

DOI:

https://doi.org/10.7439/ijbr.v6i11.2639

Abstract

Background: Oral squamous cell carcinoma (SCC) is one of the most frequent cancers in the world. The overall postoperative survival has not improved much despite advanced surgical techniques and anticancer drugs. A better understanding of molecular mechanisms and identification of potential oncogenes in oral carcinomas may provide new therapeutic decisions such as target therapy in the treatment of these patients. Aims and objectives: The present study aimed at analyzing the clinicopathological profile of patients with oral SCC and also, to determine the levels of expression of EGFR and Her-2 neu in these lesions and carry out their correlation with the clinicopathological parameters. Material and Methods: The expression of EGFR and Her-2 neu was studied in paraffin embedded tissue sections of oral SCC after taking a detailed history and examination. Results and Conclusion: EGFR was positively expressed in 84.4% (38/45) of squamous cell carcinomas and 79% (19/24) of dysplasias. While Her-2 neu was positively expressed in 62.2% (28/45) of carcinomas and 66.7% (16/24) of dysplasias. The correlation between tumor differentiation and immunomarker expression came out to be significant for EGFR but not Her-2 neu. Thus, a high level of EGFR is strongly associated with tumor aggressiveness. Molecular targeting of EGFR can therefore, is used for adjuvant treatment in malignancy.

Downloads

Download data is not yet available.

Author Biographies

  • Varsha Dalal, National Institute of Pathology, Indian Council of Medical Research
    Senior Resident, National Institute of Pathology
  • Kiran Alam, J.N Medical College, AMU
    Professor, Department of Pathology
  • Veena Maheshwari, J.N Medical College, AMU
    Professor, Department of Pathology
  • S.C Sharma, J.N Medical College, AMU
    Professor, Department of Otorhinolaryngology
  • Anshu Jain, J.N Medical College, AMU
    Assistant Professor,Department of Pathology
  • Roobina Khan, J.N Medical College, AMU
    Assistant Professor, Department of Pathology

References

Siddiqui IA, Farooq MU, Siddiqui RA, Rafi SMT () Role of toluidine blue in early detection of oral cancer. Pak J Med Sci 2006; 22: 184-7.

Byakodi R, Byakodi S, Hiremath S, Byakodi J, Adaki S, Marathe M et al. Oral Cancer in India: An Epidemiologic and Clinical Review. J Community Health 2012; 37: 316

Mehrotra R, Yadav S. Oral squamous cell carcinoma: etiology, pathogenesis and prognostic value of genomic alterations. Indian J Cancer 2006; 43: 60-6.

Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer Cancer Medicine. Philadelphia: Williams and Wilkins 1996; 1645

Chen, I. H., J. T. Chang, C. T. Liao, H. M. Wang, L. L. Hsieh, and A. J. Cheng. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area. British Journal of Cancer 2003; 89: 681-686.

Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007; 13: 285

Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology & Laboratory Medicine 2007; 131(1): 18-43.

Oliveira S, van Bergen en Henegouwen PM, Storm G, Schiffelers RM. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin Biol Ther 2006; 6(6): 605

Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2010; 2:13.

Ryott M, Wangsa D, Heselmeyer-Haddad K, Lindholm J, Elmberger G, Auer G, AvallLundqvist E, Ried T, Munck- Wikland E.EGFR protein overexpression and gene copynumber increases in oral tongue squamous cell carcinoma. Eur J Cancer 2009; 45(9):1700

O-charoenrat P, Rhys-Evans PH, Modjtahedi H, EcclesSA. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 2002; 38(7): 627-640.

Sakai H, Kawano K, Hishimoto N. Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma. J Oral Pathol Med 1990; 19: 1

Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Hensen GN, Bretlau P. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinoma. Eur Arch Otorhinolaryngol 1992; 249(5): 243

Laimer K, Spizzo G, Gastl G,Obrist P, BrunhuberTh, Fong D et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncology2007; 43:193

Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8(3): 885

Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC 2005; 5: 62.

Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11(4): 689

Bernardes VF, Gleber-Netto FO, Sousa SF, Silva TA, Aquiar MC. Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: A case control study. J Exp Clin Cancer Res 2010; 29: 40.

Bernardes VF, Gleber- Netto FO, Sousa SF, Rocha RM, Aquiar MC. EGFR status in oral squamouscell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series study. BMJ Open 2013; 3:e002077.

Yamada T, Takagi M, Shioda S. Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol 1992; 73: 67

Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Archives of Otolaryngology

Seifi S, Shafaei S, NosratiKaAriaeifar B. Lack of Elevated HER2/neu Expression in Epithelial Dysplasia and Oral Squamous Cell Carcinoma in Iran. Asian Pacific J Cancer Prev 2009; 10: 661-664

Fong Y, Chou SJ, Hung KF, Wu HT, Kao SY. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. J Chin Med Assoc 2008; 71(3): 123

Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002; 8: 540

Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5: 4164

Mahendra et al.

Shafer WG, Hine MK, and Levy BM. Benign and malignant tumors of oral cavity. In Shafer's Textbook of Oral Pathology, 2006; Elsevier, 5thEd.

Ribeiro FA, Noguti J, Oshima CT, Ribeiro DA. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res. 2014; 34(4), 1547-52.

Bundela S, Sharma A, Bisen PS. Potential therapeutic targets for oral cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70. PLoS One. 2014; 16: 9(7):e102610. Doi: 10.1371/journal.pone.0102610.

Downloads

Published

2015-11-30

Issue

Section

Original Research Articles

How to Cite

1.
Correlation of clinicopathological parameters with EGFR and Her-2 neu status in oral cancer patients in a tertiary care centre. Int Jour of Biomed Res [Internet]. 2015 Nov. 30 [cited 2026 Mar. 31];6(11):897-902. Available from: https://ssjournals.co.in/index.php/ijbr/article/view/2639